Biodesix will showcase its R&D roadmap and diagnostic innovations at the 2025 AMP Annual Meeting in Boston.
Quiver AI Summary
Biodesix, Inc., a diagnostics solutions company, will participate in the 2025 AMP Annual Meeting in Boston, MA, from November 12-15. On November 12, Dr. Gary Pestano will lead a Corporate Workshop focusing on Biodesix's R&D roadmap, discussing novel diagnostic services and highlighting partnerships with institutions like Memorial Sloan Kettering Cancer Center and Thermo Fisher Scientific. The workshop will cover advancements in molecular diagnostic testing, emphasizing quick results, high throughput, and efficient sample use through technologies like NGS and mass spectrometry. Additionally, on November 15, staff scientist Leisa Jackson will present a poster on the impact of blood collection tubes on a device for enriching circulating tumor cells. Biodesix aims to enhance patient care through innovative diagnostic tests and partnerships in the healthcare sector.
Potential Positives
- Biodesix is showcasing its R&D Roadmap and innovations in diagnostic services at a prominent industry event, enhancing its visibility in the diagnostics field.
- The involvement of key partners like Memorial Sloan Kettering Cancer Center, Bio-Rad Laboratories, and Thermo Fisher Scientific highlights the strength of Biodesix's collaborations and credibility in the industry.
- The presentation of clinically relevant studies and advancements in molecular diagnostics during the workshop emphasizes Biodesix's commitment to improving patient care and outcomes.
- Biodesix's participation at the AMP Annual Meeting demonstrates their active role in advancing diagnostic technologies, potentially attracting new partnerships and customers.
Potential Negatives
- Potential overemphasis on R&D roadmap and upcoming innovations may indicate a lack of currently marketable products, raising concerns about the company’s immediate revenue generation capabilities.
- The reliance on partnerships with major institutions like Memorial Sloan Kettering may suggest that the company is dependent on external validation rather than showcasing its own strengths.
- Workshop titles and descriptions could imply that existing diagnostic solutions may not yet meet the desired standards for accuracy and efficiency, signaling possible gaps in their current offerings.
FAQ
What is the focus of the Biodesix Corporate Workshop at the AMP Annual Meeting?
The workshop will explore Biodesix's R&D Roadmap and novel diagnostic services for improved patient care.
When will Biodesix present its workshop at the AMP Annual Meeting?
The workshop is scheduled for November 12 at 4:00 ET during the 2025 AMP Annual Meeting in Boston.
Who will lead the Biodesix Corporate Workshop?
Dr. Gary Pestano, Chief Development Officer at Biodesix, will lead the workshop.
What will the poster presentation by Leisa Jackson entail?
Leisa Jackson will present on the impact of blood collection tubes on the performance of a novel device for enriching circulating tumor cells.
Where can I find more information about Biodesix's offerings?
For more details, visit the Biodesix website at biodesix.com.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$BDSX Insider Trading Activity
$BDSX insiders have traded $BDSX stock on the open market 21 times in the past 6 months. Of those trades, 6 have been purchases and 15 have been sales.
Here’s a breakdown of recent trading of $BDSX stock by insiders over the last 6 months:
- JACK W SCHULER has made 6 purchases buying 8,372,029 shares for an estimated $3,928,046 and 0 sales.
- SCOTT HUTTON (President & CEO) has made 0 purchases and 3 sales selling 7,547 shares for an estimated $2,914.
- ROBIN HARPER COWIE (CFO, Sec'y & Treasurer) has made 0 purchases and 3 sales selling 1,980 shares for an estimated $764.
- KIERAN O'KANE (Chief Commercial Officer) has made 0 purchases and 3 sales selling 953 shares for an estimated $368.
- GARY ANTHONY PESTANO (Chief Development Officer) has made 0 purchases and 3 sales selling 887 shares for an estimated $342.
- CHRIS VAZQUEZ (Chief Accounting Officer) has made 0 purchases and 3 sales selling 452 shares for an estimated $174.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$BDSX Hedge Fund Activity
We have seen 13 institutional investors add shares of $BDSX stock to their portfolio, and 34 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- AIGH CAPITAL MANAGEMENT LLC removed 4,272,591 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $1,205,725
- OPALEYE MANAGEMENT INC. removed 3,225,000 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $910,095
- SILVERARC CAPITAL MANAGEMENT, LLC removed 3,028,039 shares (-73.9%) from their portfolio in Q2 2025, for an estimated $854,512
- SAMJO MANAGEMENT, LLC removed 2,408,100 shares (-99.0%) from their portfolio in Q2 2025, for an estimated $679,565
- MONASHEE INVESTMENT MANAGEMENT LLC removed 2,050,000 shares (-50.6%) from their portfolio in Q2 2025, for an estimated $578,510
- FARALLON CAPITAL MANAGEMENT LLC removed 1,731,308 shares (-93.1%) from their portfolio in Q2 2025, for an estimated $488,575
- GSA CAPITAL PARTNERS LLP added 898,059 shares (+2694.0%) to their portfolio in Q2 2025, for an estimated $253,432
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$BDSX Analyst Ratings
Wall Street analysts have issued reports on $BDSX in the last several months. We have seen 4 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Scotiabank issued a "Sector Outperform" rating on 05/21/2025
- Craig-Hallum issued a "Buy" rating on 05/14/2025
- Lake Street issued a "Buy" rating on 05/14/2025
- Canaccord Genuity issued a "Buy" rating on 05/14/2025
To track analyst ratings and price targets for $BDSX, check out Quiver Quantitative's $BDSX forecast page.
$BDSX Price Targets
Multiple analysts have issued price targets for $BDSX recently. We have seen 4 analysts offer price targets for $BDSX in the last 6 months, with a median target of $2.0.
Here are some recent targets:
- Kyle Mikson from Canaccord Genuity set a target price of $20.0 on 09/19/2025
- Sung Ji Nam from Scotiabank set a target price of $2.0 on 05/21/2025
- Bill Bonello from Craig-Hallum set a target price of $1.5 on 05/14/2025
- Thomas Flaten from Lake Street set a target price of $2.0 on 05/14/2025
Full Release
LOUISVILLE, Colo., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostics solutions company, announces its Corporate and Scientific presentations, and exhibitor presence at the 2025 AMP Annual Meeting, November 12-15, in Boston, MA.
BIODESIX WORKSHOP: On November 12, at 4:00 ET, Dr. Gary Pestano, Chief Development Officer, will lead a Biodesix Corporate Workshop focused on the company’s R&D Roadmap, including both near- and longer-term novel diagnostic services and solutions. The panel will include updates from key partners of Biodesix Development Services: Memorial Sloan Kettering Cancer Center, Bio-Rad Laboratories, and Thermo Fisher Scientific.
WORKSHOP TITLE: Biodesix & New Approaches to Comprehensive Molecular Testing: Focus on Accurate Results with Rapid Turn-around, High-throughput, and Low Sample Requirements for Diagnosis and Monitoring.
WORKSHOP DESCRIPTION: Recent advances in diagnostic laboratory testing have been focused on molecular readouts as key technologies. Biodesix has assembled a panel of subject matter experts drawn from its academic and industry partner network, who will share clinically relevant studies to demonstrate how advances in turn-around time to results, increased throughput, and maximized sample use are driving new test development and utility in the clinical laboratory. The molecular diagnostic approaches presented will include newer approaches integrating NGS, ddPCR, and Mass Spectrometry. Studies presented will include clinical diagnostic utility, as well as advanced research concepts in monitoring therapeutic response.
A recording of this presentation will be made available on the company website.
In addition, Biodesix executives, scientists, and expert consultants will be present at booth #647 to discuss Biodesix Development Services offerings.
“Biomarkers are poised to transform and improve patient care across many disease states,” said Scott Hutton, CEO at Biodesix. "We’re looking forward to Gary sharing our R&D Roadmap with a focus on innovations in the pipeline and our strategic partnerships. Including some of our key partners in our Corporate Workshop reinforces the strength of the deep collaborations we have established to deliver specialized IVD and LDT services.”
POSTER PRESENTATION: On November 15, Leisa Jackson, Staff Scientist at Biodesix, will present a poster: “ Assessing the impact of blood collection tubes on the performance of a novel device for enrichment of circulating tumor cells .”
About Biodesix:
Biodesix is a leading diagnostic solutions company, driven to improve clinical care and outcomes for patients. Biodesix Diagnostic Tests , marketed as Nodify Lung® Nodule Risk Assessment and IQLung® Cancer Treatment Guidance, support clinical decisions to expedite personalized care and improve outcomes for patients with lung disease. Biodesix Development Services enable the world’s leading biopharmaceutical, life sciences, and research institutions with scientific, technological, and operational capabilities that fuel the development of diagnostic tests, tools, and therapeutics. For more information, visit biodesix.com.
Biodesix Contacts:
Media:
Natalie St. Denis, Director Corporate Communications, Biodesix
[email protected]
(720) 925-9285
Investors:
Chris Brinzey, Partner, ICR
[email protected]
(339) 970-2843
